Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

7

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Estrogen receptor

7

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

7

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Dysfunctional uterine bleeding

7

Ovarian cancer

7

Postmenopausal bone loss

7

Pregnancy

7

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

7

Primary

7

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Central Drug Research Institute

7

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

7

PUBCHEM

7

CAS

6

EPA CompTox

4

MERCK INDEX

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

GENITO URINARY SYSTEM AND SEX HORMONES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Selective estrogen receptor modulators

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 7 of 7 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

7-DESMETHYLORMELOXIFENE, (-)-

3JG8WB8GBG

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

ORMELOXIFENE

44AXY5VE90

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

ORMELOXIFENE FUMARATE

4R59J5G61K

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

ORMELOXIFENE HYDROCHLORIDE

GL3LAI70F3

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

7-DESMETHYLORMELOXIFENE

Z524X388WM

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

LEVORMELOXIFENE FUMARATE

2XFK7X56Q3

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

LEVORMELOXIFENE

9512UKZ352

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Estrogen receptor

Estrogen receptor

Conditions:

Dysfunctional uterine bleeding

Postmenopausal bone loss

Levormeloxifene (INN) is an experimental selective estrogen receptor modulator (SERM) that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. Levormeloxifene is the levo...

rotatory enantiomer of non-hormonal, non-steroidal oral contraceptive -- ormeloxifene (trade names Novex-DS, Centron, and Sevista). The development of Levormeloxifene was stopped because of a high incidence of gynecologic adverse events during clinical trials.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1